PTC Therapeutics, Inc. (PTCT) is a publicly traded Healthcare sector company. As of July 13, 2026, PTCT trades at $84.85 with a market cap of $7.04B and a P/E ratio of -34.21. PTCT moved +0.00% today. Year to date, PTCT is +11.37%; over the trailing twelve months it is +71.34%. Its 52-week range spans $35.95 to $90.87. Analyst consensus is strong buy with an average price target of $97.60. Rallies surfaces PTCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
11 analysts cover PTCT: 0 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $97.60.
| Metric | Value |
|---|---|
| Price | $84.85 |
| Market Cap | $7.04B |
| P/E Ratio | -34.21 |
| EPS | $-2.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $90.87 |
| 52-Week Low | $35.95 |
| Volume | 444 |
| Avg Volume | 0 |
| Revenue (TTM) | $827.11M |
| Net Income | $-186.73M |
| Gross Margin | 0.00% |
11 analysts cover PTCT: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $97.60.